Cargando…

Efficacy of an oral formulation of afoxolaner and milbemycin oxime against Tunga penetrans in naturally infected dogs

BACKGROUND: The sand flea Tunga penetrans is one of the agents of tungiasis, an important parasitic skin disease affecting humans and several mammalian species. Tungiasis is mainly observed in disadvantaged rural and peripheral urban communities in Latin America and sub-Saharan Africa. The dog is a...

Descripción completa

Detalles Bibliográficos
Autores principales: dos Santos, Katharine Costa, Tielemans, Eric, Cutolo, Andre Antonio, Guedes, Paula Elisa Brandão, Harvey, Tatiani Vitor, de Carvalho Teixeira, Jamille Bispo, Vitor, Rebeca Costa, da Paixão Sevá, Anaiá, de Melo Navarro, Adan William, Lima, Ana Carolina Ribeiro, Botteon, Karin Denise, Bittar, Thammy Vieira, Albuquerque, George Rêgo, de Almeida Borges, Fernando, Beugnet, Frederic, Carlos, Renata Santiago Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693705/
https://www.ncbi.nlm.nih.gov/pubmed/38042848
http://dx.doi.org/10.1186/s13071-023-06063-x
_version_ 1785153219290202112
author dos Santos, Katharine Costa
Tielemans, Eric
Cutolo, Andre Antonio
Guedes, Paula Elisa Brandão
Harvey, Tatiani Vitor
de Carvalho Teixeira, Jamille Bispo
Vitor, Rebeca Costa
da Paixão Sevá, Anaiá
de Melo Navarro, Adan William
Lima, Ana Carolina Ribeiro
Botteon, Karin Denise
Bittar, Thammy Vieira
Albuquerque, George Rêgo
de Almeida Borges, Fernando
Beugnet, Frederic
Carlos, Renata Santiago Alberto
author_facet dos Santos, Katharine Costa
Tielemans, Eric
Cutolo, Andre Antonio
Guedes, Paula Elisa Brandão
Harvey, Tatiani Vitor
de Carvalho Teixeira, Jamille Bispo
Vitor, Rebeca Costa
da Paixão Sevá, Anaiá
de Melo Navarro, Adan William
Lima, Ana Carolina Ribeiro
Botteon, Karin Denise
Bittar, Thammy Vieira
Albuquerque, George Rêgo
de Almeida Borges, Fernando
Beugnet, Frederic
Carlos, Renata Santiago Alberto
author_sort dos Santos, Katharine Costa
collection PubMed
description BACKGROUND: The sand flea Tunga penetrans is one of the agents of tungiasis, an important parasitic skin disease affecting humans and several mammalian species. Tungiasis is mainly observed in disadvantaged rural and peripheral urban communities in Latin America and sub-Saharan Africa. The dog is a major reservoir of Tunga fleas. Hematophagous adult female Tunga spp. embed and grow in their host’s epidermis and cause cutaneous inflammatory disorders. NexGard Spectra(®) is an orally administered endectocide for dogs, a co-formulation of the isoxazoline afoxolaner and the macrocyclic lactone milbemycin oxime. The objective of this study was to assess the efficacy of this product against canine tungiasis. METHODS: A blinded, negative-controlled field trial was conducted in a Brazilian community known to be highly endemic for tungiasis. Sixty-six dogs naturally infected with live T. penetrans were randomly allocated to a treated group (44 dogs) and an untreated control group (22 dogs). In a first phase, dogs from the treated group were treated on days 0, 30, and 60. Efficacy was evaluated on the basis of the macroscopic parasitic skin lesions (Fortaleza classification) on days 7, 14, 21, 30, 45, 60, 75, and 90. In a second phase, to evaluate natural reinfections, all dogs were treated on day 90 and evaluated every 2 weeks thereafter until at least 30% of dogs were infected with live sand fleas. RESULTS: During the first phase, efficacy (reduction in live sand fleas) of 92.4% was demonstrated on day 7. From day 14 until day 90, the efficacy of NexGard Spectra(®) was 100%. In the second phase, all dogs were free of live T. penetrans from 15 until 45 days after the day 90 treatment; 60 days post-treatment, 11% of dogs were reinfected, and 75 days post-treatment, 40% of dogs were reinfected. CONCLUSIONS: NexGard Spectra(®) was demonstrated to be highly effective against canine tungiasis. In addition to an obvious beneficial effect on the health and welfare of the treated dog, the use of this product may have a one-health benefit on human cases by controlling the main reservoir of sand fleas. GRAPHICAL ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-10693705
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106937052023-12-04 Efficacy of an oral formulation of afoxolaner and milbemycin oxime against Tunga penetrans in naturally infected dogs dos Santos, Katharine Costa Tielemans, Eric Cutolo, Andre Antonio Guedes, Paula Elisa Brandão Harvey, Tatiani Vitor de Carvalho Teixeira, Jamille Bispo Vitor, Rebeca Costa da Paixão Sevá, Anaiá de Melo Navarro, Adan William Lima, Ana Carolina Ribeiro Botteon, Karin Denise Bittar, Thammy Vieira Albuquerque, George Rêgo de Almeida Borges, Fernando Beugnet, Frederic Carlos, Renata Santiago Alberto Parasit Vectors Research BACKGROUND: The sand flea Tunga penetrans is one of the agents of tungiasis, an important parasitic skin disease affecting humans and several mammalian species. Tungiasis is mainly observed in disadvantaged rural and peripheral urban communities in Latin America and sub-Saharan Africa. The dog is a major reservoir of Tunga fleas. Hematophagous adult female Tunga spp. embed and grow in their host’s epidermis and cause cutaneous inflammatory disorders. NexGard Spectra(®) is an orally administered endectocide for dogs, a co-formulation of the isoxazoline afoxolaner and the macrocyclic lactone milbemycin oxime. The objective of this study was to assess the efficacy of this product against canine tungiasis. METHODS: A blinded, negative-controlled field trial was conducted in a Brazilian community known to be highly endemic for tungiasis. Sixty-six dogs naturally infected with live T. penetrans were randomly allocated to a treated group (44 dogs) and an untreated control group (22 dogs). In a first phase, dogs from the treated group were treated on days 0, 30, and 60. Efficacy was evaluated on the basis of the macroscopic parasitic skin lesions (Fortaleza classification) on days 7, 14, 21, 30, 45, 60, 75, and 90. In a second phase, to evaluate natural reinfections, all dogs were treated on day 90 and evaluated every 2 weeks thereafter until at least 30% of dogs were infected with live sand fleas. RESULTS: During the first phase, efficacy (reduction in live sand fleas) of 92.4% was demonstrated on day 7. From day 14 until day 90, the efficacy of NexGard Spectra(®) was 100%. In the second phase, all dogs were free of live T. penetrans from 15 until 45 days after the day 90 treatment; 60 days post-treatment, 11% of dogs were reinfected, and 75 days post-treatment, 40% of dogs were reinfected. CONCLUSIONS: NexGard Spectra(®) was demonstrated to be highly effective against canine tungiasis. In addition to an obvious beneficial effect on the health and welfare of the treated dog, the use of this product may have a one-health benefit on human cases by controlling the main reservoir of sand fleas. GRAPHICAL ABSTRACT: [Image: see text] BioMed Central 2023-12-02 /pmc/articles/PMC10693705/ /pubmed/38042848 http://dx.doi.org/10.1186/s13071-023-06063-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
dos Santos, Katharine Costa
Tielemans, Eric
Cutolo, Andre Antonio
Guedes, Paula Elisa Brandão
Harvey, Tatiani Vitor
de Carvalho Teixeira, Jamille Bispo
Vitor, Rebeca Costa
da Paixão Sevá, Anaiá
de Melo Navarro, Adan William
Lima, Ana Carolina Ribeiro
Botteon, Karin Denise
Bittar, Thammy Vieira
Albuquerque, George Rêgo
de Almeida Borges, Fernando
Beugnet, Frederic
Carlos, Renata Santiago Alberto
Efficacy of an oral formulation of afoxolaner and milbemycin oxime against Tunga penetrans in naturally infected dogs
title Efficacy of an oral formulation of afoxolaner and milbemycin oxime against Tunga penetrans in naturally infected dogs
title_full Efficacy of an oral formulation of afoxolaner and milbemycin oxime against Tunga penetrans in naturally infected dogs
title_fullStr Efficacy of an oral formulation of afoxolaner and milbemycin oxime against Tunga penetrans in naturally infected dogs
title_full_unstemmed Efficacy of an oral formulation of afoxolaner and milbemycin oxime against Tunga penetrans in naturally infected dogs
title_short Efficacy of an oral formulation of afoxolaner and milbemycin oxime against Tunga penetrans in naturally infected dogs
title_sort efficacy of an oral formulation of afoxolaner and milbemycin oxime against tunga penetrans in naturally infected dogs
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693705/
https://www.ncbi.nlm.nih.gov/pubmed/38042848
http://dx.doi.org/10.1186/s13071-023-06063-x
work_keys_str_mv AT dossantoskatharinecosta efficacyofanoralformulationofafoxolanerandmilbemycinoximeagainsttungapenetransinnaturallyinfecteddogs
AT tielemanseric efficacyofanoralformulationofafoxolanerandmilbemycinoximeagainsttungapenetransinnaturallyinfecteddogs
AT cutoloandreantonio efficacyofanoralformulationofafoxolanerandmilbemycinoximeagainsttungapenetransinnaturallyinfecteddogs
AT guedespaulaelisabrandao efficacyofanoralformulationofafoxolanerandmilbemycinoximeagainsttungapenetransinnaturallyinfecteddogs
AT harveytatianivitor efficacyofanoralformulationofafoxolanerandmilbemycinoximeagainsttungapenetransinnaturallyinfecteddogs
AT decarvalhoteixeirajamillebispo efficacyofanoralformulationofafoxolanerandmilbemycinoximeagainsttungapenetransinnaturallyinfecteddogs
AT vitorrebecacosta efficacyofanoralformulationofafoxolanerandmilbemycinoximeagainsttungapenetransinnaturallyinfecteddogs
AT dapaixaosevaanaia efficacyofanoralformulationofafoxolanerandmilbemycinoximeagainsttungapenetransinnaturallyinfecteddogs
AT demelonavarroadanwilliam efficacyofanoralformulationofafoxolanerandmilbemycinoximeagainsttungapenetransinnaturallyinfecteddogs
AT limaanacarolinaribeiro efficacyofanoralformulationofafoxolanerandmilbemycinoximeagainsttungapenetransinnaturallyinfecteddogs
AT botteonkarindenise efficacyofanoralformulationofafoxolanerandmilbemycinoximeagainsttungapenetransinnaturallyinfecteddogs
AT bittarthammyvieira efficacyofanoralformulationofafoxolanerandmilbemycinoximeagainsttungapenetransinnaturallyinfecteddogs
AT albuquerquegeorgerego efficacyofanoralformulationofafoxolanerandmilbemycinoximeagainsttungapenetransinnaturallyinfecteddogs
AT dealmeidaborgesfernando efficacyofanoralformulationofafoxolanerandmilbemycinoximeagainsttungapenetransinnaturallyinfecteddogs
AT beugnetfrederic efficacyofanoralformulationofafoxolanerandmilbemycinoximeagainsttungapenetransinnaturallyinfecteddogs
AT carlosrenatasantiagoalberto efficacyofanoralformulationofafoxolanerandmilbemycinoximeagainsttungapenetransinnaturallyinfecteddogs